Quoc Tuan Do

Chemoinformatics Manager at Greenpharma S.A.S.

France · OrléansJoined November -0001

Summary

I work in molecular modelling/chemoinformatics for 20 years, developing virtual screening tools to select active molecules or to find new applications to existing compounds. I am also involved in chemical library design and data mining (eg GPDB covering 155000 natural products, 160000 organisms, traditional usage, biological data, protein targets).

Research areas of interest (9)

  • Fine Chemicals, Dyes and Inks
  • Biological Sciences
  • Heart and blood circulation illnesses
  • Pharmaceutical Products / Drugs
  • Agriculture and Marine Resources
  • and 4 more

Quoc Tuan Do didn't publish any Technology Call yet

Quoc Tuan Do didn't publish any Technology Offer Offer yet

VSPrep: A General KNIME Workflow for the Preparation of Molecules for Virtual Screening.

Gally JM, Bourg S, Do QT, Aci-Sèche S, Bonnet P.
Over the past decades, virtual screening has proved itself to be a valuable asset to identify new bioactive compounds. The vast majority of commonly used techniques can be described in three steps: pre-processing the dataset i. e. small (ligands) and eventually larger (receptors) molecules, execute the method and finally analyse the results. Hence, the preparation of ligands is a critical step for success of commonly used virtual screening approaches such as protein-ligand docking, similarity or pharmacophore search. We present here a new workflow, VSPrep, for the pre-processing of small molecules; it is based on freely accessible tools for academics and is integrated within the KNIME platform. It can be used to perform several chemoinformatics tasks such as molecular database cleaning, tautomer and stereoisomer enumeration, focused library design and conformer generation. Additionally, graphical reports of the results are provided to the user as a convenient analysis tool.

Myocardial fibrosis: biomedical research from bench to bedside.

Gyöngyösi M, Winkler J, Ramos I, Do QT, Firat H, McDonald K, González A, Thum T, Díez J, Jaisser F, Pizard A, Zannad F.
Myocardial fibrosis refers to a variety of quantitative and qualitative changes in the interstitial myocardial collagen network that occur in response to cardiac ischaemic insults, systemic diseases, drugs, or any other harmful stimulus affecting the circulatory system or the heart itself. Myocardial fibrosis alters the architecture of the myocardium, facilitating the development of cardiac dysfunction, also inducing arrhythmias, influencing the clinical course and outcome of heart failure patients. Focusing on myocardial fibrosis may potentially improve patient care through the targeted diagnosis and treatment of emerging fibrotic pathways. The European Commission funded the FIBROTARGETS consortium as a multinational academic and industrial consortium with the primary aim of performing a systematic and collaborative search of targets of myocardial fibrosis, and then translating these mechanisms into individualized diagnostic tools and specific therapeutic pharmacological options for heart failure. This review focuses on those methodological and technological aspects considered and developed by the consortium to facilitate the transfer of the new mechanistic knowledge on myocardial fibrosis into potential biomedical applications.

A strategy to discover decoy chemokine ligands with an anti-inflammatory activity.

Abboud D, Daubeuf F, Do QT, Utard V, Villa P, Haiech J, Bonnet D, Hibert M, Bernard P, Galzi JL, Frossard N.
Excessive signaling by chemokines has been associated with chronic inflammation or cancer, thus attracting substantial attention as promising therapeutic targets. Inspired by chemokine-clearing molecules shaped by pathogens to escape the immune system, we designed a generic screening assay to discover chemokine neutralizing molecules (neutraligands) and unambiguously distinguish them from molecules that block the receptor (receptor antagonists). This assay, called TRIC-r, combines time-resolved intracellular calcium recordings with pre-incubation of bioactive compounds either with the chemokine or the receptor-expressing cells. We describe here the identification of high affinity neutraligands of CCL17 and CCL22, two chemokines involved in the Th2-type of lung inflammation. The decoy molecules inhibit in vitro CCL17- or CCL22-induced intracellular calcium responses, CCR4 endocytosis and human T cell migration. In vivo, they inhibit inflammation in a murine model of asthma, in particular the recruitment of eosinophils, dendritic cells and CD4(+)T cells. Altogether, we developed a successful strategy to discover as new class of pharmacological tools to potently control cell chemotaxis in vitro and in vivo.

How to Valorize Biodiversity? Let's Go Hashing, Extracting, Filtering, Mining, Fishing.

Do QT, Medina-Franco JL, Scior T, Bernard P.
Nature was and still is a prolific source of inspiration in pharmacy, cosmetics, and agro-food industries for the discovery of bioactive products. Informatics is now present in most human activities. Research in natural products is no exception. In silico tools may help in numerous cases when studying natural substances: in pharmacognosy, to store and structure the large and increasing number of data, and to facilitate or accelerate the analysis of natural products in regards to traditional uses of natural resources; in drug discovery, to rationally design libraries for screening natural compound mimetics and identification of biological activities for natural products. Here we review different aspects of in silico approaches applied to the research and development of bioactive substances and give examples of using nature-inspiring power and ultimately valorize biodiversity.

Quoc Tuan Do didn't publish any Event yet

Quoc Tuan Do didn't publish any Job yet

Quoc Tuan Do didn't publish any New and Article yet

Quoc Tuan Do didn't publish any Education Resource yet

You are signed out

Join Innoget to connect with Quoc Tuan Do and thousands
of innovation-driven professionals and organizations